Making AI Work for Drug Discovery: A Joined-up Approach

2024 has been a year of remarkable technological advancements for the pharmaceutical industry, driven by breakthroughs in Artificial Intelligence (AI). While AI holds immense promise, the challenge for large pharma in 2025 will be executing the right strategies to unlock AI’s full potential and achieve tangible returns on investment.

CSO Ben Sidders speaks with the Journal for Clinical Studies

Biorelate Ltd. CEO and Founder Daniel Jamieson is interviewed alongside other leading pharma thinkers in the PharmaTimes Media Ltd front cover story on reflections and prediction in Pharma